| 多西紫杉醇联合顺铂治疗蒽环类耐药的晚期乳腺癌 |
| |
| 引用本文： | Hailin Xiong Zhujun Liu Xin Cheng Kai Li. 多西紫杉醇联合顺铂治疗蒽环类耐药的晚期乳腺癌[J]. 中德临床肿瘤学杂志, 2007, 6(1): 55-58. DOI: 10.1007/s10330-006-0031-y |
| |
| 作者姓名： | Hailin Xiong Zhujun Liu Xin Cheng Kai Li |
| |
| 作者单位： | No. 3rd Department of Medical Oncology, the Affiliated Cancer Hospital of Tianjin Medical University, Tianjin 300060, China |
| |
| 摘 要： | Objective： To observe the effect and toxicity of docetaxel with cisplatin in anthracyclines-resistant advanced breast cancer. Methods： Forty-five female patients received docetaxel 60 mg/m^2 on dl and cisplatin 30 mg/m^2 on d1-d3 of every 28 days. Every patient was treated with at least 2 cycles and a median of 3 cycles （2-6 cycles ）. Results： Five patients achieved complete response （11.1%） and 18 partial response （40.0%）, 10 stable disease （22.2%）. The overall response rate was 51.1%. The clinical disease control rate was 73.3%, median time to tumor progression （TTP） was 7.8 months （1.0-34.5 months）, median survival time was 17.6 months （range 1.9-48.0 months）, and one year survival rate was 65.2%. The main side effect was marrow suppression. The treatment was well tolerated with grades Ⅲ and Ⅳ leukopenia in nine （20%） and ten （22.2%） patients. Conclusion： Combinative chemotherapy of docetaxel and cisplatin has a good anti-tumor activity on refractory advanced breast cancer with manageable toxicity.
|
| 关 键 词： | 晚期乳腺癌 蒽环类耐药 多烯紫杉醇 顺铂 联合化疗 治疗 |
| 收稿时间： | 2006-12-03 |
| 修稿时间： | 2007-01-10 |
Docetaxel and cisplatin combination chemotherapy in anthracyclines-resistant advanced breast cancer |
| |
| Hailin Xiong,Zhujun Liu,Xin Cheng,Kai Li. Docetaxel and cisplatin combination chemotherapy in anthracyclines-resistant advanced breast cancer[J]. The Chinese-German Journal of Clinical Oncology, 2007, 6(1): 55-58. DOI: 10.1007/s10330-006-0031-y |
| |
| Authors: | Hailin Xiong Zhujun Liu Xin Cheng Kai Li |
| |
| Affiliation: | (1) No. 3rd Department of Medical Oncology, the Affiliated Cancer Hospital of Tianjin Medical University, Tianjin, 300060, China |
| |
| Abstract: | Objective: To observe the effect and toxicity of docetaxel with cisplatin in anthracyclines-resistant advanced breast cancer. Methods: Forty-five female patients received docetaxel 60 mg/m2 on d1 and cisplatin 30 mg/m2 on d1-d3 of every 28 days. Every patient was treated with at least 2 cycles and a median of 3 cycles (2-6 cycles ). Results: Five patients achieved complete response (11.1%) and 18 partial response (40.0%), 10 stable disease (22.2%). The overall response rate was 51.1%. The clinical disease control rate was 73.3%, median time to tumor progression (TTP) was 7.8 months (1.0-34.5months), median survival time was 17.6 months (range 1.9-48.0 months), and one year survival rate was 65.2%. The main side effect was marrow suppression. The treatment was well tolerated with grades Ⅲ and Ⅳ leukopenia in nine (20%) and ten (22.2%) patients.Conclusion:Combinative chemotherapy of docetaxel and cisplatin has a good anti-tumor activity on refractory advanced breast cancer cancer with manageable toxicity. |
| |
| Keywords: | breast cancer docetaxel cisplatin combinative chemotherapy |
| 本文献已被 CNKI 维普 万方数据 SpringerLink 等数据库收录！ |
